Novartis shelves potential blockbuster pelacarsen as landmark study fails
Novartis has shelved development of pelacarsen after a landmark study failed to meet its goals. The decision halts a drug that had been considered a potential blockbuster.
Novartis pelacarsen clinical study drug development trial failure